FOAMmedic ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  18.2% 18.2% 8.9% 28.2% 23.7%  
Credit score (0-100)  9 8 26 1 3  
Credit rating  B B BB B B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  3.4 96.2 10.7 -7.1 -10.2  
EBITDA  3.4 96.2 10.7 -7.1 -10.2  
EBIT  3.4 96.2 10.7 -7.1 -10.2  
Pre-tax profit (PTP)  2.1 94.7 9.7 -9.7 -16.5  
Net earnings  0.2 73.6 7.1 -8.6 -17.6  
Pre-tax profit without non-rec. items  2.1 94.7 9.7 -9.7 -16.5  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.2 73.7 80.8 72.3 54.6  
Interest-bearing liabilities  0.0 0.2 0.0 0.0 0.0  
Balance sheet total (assets)  90.6 124 125 90.1 69.2  

Net Debt  -35.4 -98.3 -102 -84.6 -59.9  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  3.4 96.2 10.7 -7.1 -10.2  
Gross profit growth  0.0% 2,705.6% -88.9% 0.0% -44.3%  
Employees  4 4 4 1 1  
Employee growth %  0.0% 0.0% 0.0% -75.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  91 124 125 90 69  
Balance sheet change%  0.0% 36.5% 1.3% -28.1% -23.2%  
Added value  3.4 96.2 10.7 -7.1 -10.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 -1.0 -2.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  3.8% 89.8% 8.6% -6.6% -12.6%  
ROI %  2,017.1% 259.5% 13.8% -9.2% -15.9%  
ROE %  97.6% 199.1% 9.2% -11.2% -27.8%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.2% 59.6% 64.5% 80.2% 79.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -1,032.4% -102.1% -955.8% 1,195.2% 586.5%  
Gearing %  0.0% 0.3% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 1,240.8% 865.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  1.0 2.5 2.8 5.0 4.8  
Current Ratio  1.0 2.5 2.8 5.0 4.8  
Cash and cash equivalent  35.4 98.5 102.2 84.6 59.9  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.2 73.7 80.8 72.3 54.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  1 24 3 -7 -10  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  1 24 3 -7 -10  
EBIT / employee  1 24 3 -7 -10  
Net earnings / employee  0 18 2 -9 -18